BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Vachher M, Bansal S, Kumar B, Yadav S, Burman A. Deciphering the role of aberrant DNA methylation in NAFLD and NASH. Heliyon 2022;8:e11119. [PMID: 36299516 DOI: 10.1016/j.heliyon.2022.e11119] [Reference Citation Analysis]
2 Mangia A, Piazzolla AV, Squillante MM, Cocomazzi G, Valori VM, Copetti M, Parente P, Attino V, Guido M. Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study. J Clin Med 2022;11:5969. [PMID: 36233834 DOI: 10.3390/jcm11195969] [Reference Citation Analysis]
3 Yang MH, Li WY, Wu CF, Lee YC, Chen AY, Tyan YC, Chen YA. Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. Int J Mol Sci 2022;23:10072. [PMID: 36077467 DOI: 10.3390/ijms231710072] [Reference Citation Analysis]
4 Frasinariu O, Serban R, Trandafir LM, Miron I, Starcea M, Vasiliu I, Alisi A, Temneanu OR. The Role of Phytosterols in Nonalcoholic Fatty Liver Disease. Nutrients 2022;14:2187. [PMID: 35683987 DOI: 10.3390/nu14112187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Carrasco I, Olveira A, Lancharro Á, Escosa L, Mellado MJ, Busca C, Montes ML, Díez C, Alcolea-Ruiz S, Navarro ML, Sainz T. Prevalence of nonalcoholic fatty liver disease using noninvasive techniques among children, adolescents, and youths living with HIV. AIDS 2022;36:805-14. [PMID: 35013082 DOI: 10.1097/QAD.0000000000003170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Cominguez DC, Park YJ, Kang YM, Nugroho A, Kim S, An HJ. Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro. Sci Rep 2022;12:4154. [PMID: 35264693 DOI: 10.1038/s41598-022-07937-3] [Reference Citation Analysis]
7 Ke Y, Chen T, Tang R, Lin J, Lin F. Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD). APL Bioengineering 2022;6:016102. [DOI: 10.1063/5.0081695] [Reference Citation Analysis]
8 Yasar O, Long P, Harder B, Marshall H, Bhasin S, Lee S, Delegge M, Roy S, Doyle O, Leavitt N, Rigg J. Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). BMJ Health Care Inform 2022;29:e100510. [DOI: 10.1136/bmjhci-2021-100510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Unsal İO, Calapkulu M, Sencar ME, Cakal B, Ozbek M. Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. Sci Rep 2022;12:283. [PMID: 34997159 DOI: 10.1038/s41598-021-04361-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Hazem RM, Ibrahim AZ, Ali DA, Moustafa YM. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022;104:108503. [PMID: 34998036 DOI: 10.1016/j.intimp.2021.108503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Oza D, Amiji MM. Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases. Macrophage Targeted Delivery Systems 2022. [DOI: 10.1007/978-3-030-84164-5_16] [Reference Citation Analysis]
13 Zhang C, Yang M. Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment. Exploration of Medicine. [DOI: 10.37349/emed.2021.00066] [Reference Citation Analysis]
14 Spinosa M, Wong S. Screening for Non-alcoholic Fatty Liver Disease in Current Practice. Curr Hepatology Rep 2021;20:128-134. [DOI: 10.1007/s11901-021-00577-7] [Reference Citation Analysis]
15 Laroia ST, Vellore Srinivasan S, Yadav K, Rastogi A, Kumar S, Kumar G, Kumar M. Performance of shear wave elastography: A single centre pilot study of mixed etiology liver disease patients with normal BMI. Australas J Ultrasound Med 2021;24:120-36. [PMID: 34765422 DOI: 10.1002/ajum.12244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Arman T, Baron JA, Lynch KD, White LA, Aldan J, Clarke JD. MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period. Toxicology 2021;464:153021. [PMID: 34740672 DOI: 10.1016/j.tox.2021.153021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150-61. [PMID: 34570916 DOI: 10.1111/apt.16608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
18 Osei TB, van Dijk AM, Dingerink S, Chilunga FP, Beune E, Meeks KAC, Bahendeka S, Schulze MB, Agyemang C, Nicolaou M, Holleboom AG, Danquah I. Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. Nutrients 2021;13:3679. [PMID: 34835937 DOI: 10.3390/nu13113679] [Reference Citation Analysis]
19 Cazanave SC, Warren AD, Pacula M, Touti F, Zagorska A, Gural N, Huang EK, Sherman S, Cheema M, Ibarra S, Bates J, Billin AN, Liles JT, Budas GR, Breckenridge DG, Tiniakos D, Ratziu V, Daly AK, Govaere O, Anstee QM, Gelrud L, Luther J, Chung RT, Corey KE, Winckler W, Bhatia S, Kwong GA. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Sci Transl Med 2021;13:eabe8939. [PMID: 34669440 DOI: 10.1126/scitranslmed.abe8939] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
20 Zhao Z, Fu C, Zhang Y, Fu A. Dimeric Histidine as a Novel Free Radical Scavenger Alleviates Non-Alcoholic Liver Injury. Antioxidants (Basel) 2021;10:1529. [PMID: 34679664 DOI: 10.3390/antiox10101529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dinani A, Sussman N, Noureddin M, Fuchs M, Therapondos G, Girgrah N, Diaz VF, Mantry P, Rinella M, Asgharpour A, Dieterich D. An algorithm for the management of non-alcoholic fatty liver disease in primary care. GHOA 2021;12:114-122. [DOI: 10.15406/ghoa.2021.12.00469] [Reference Citation Analysis]
22 M. Heshmati H. Treatment of Nonalcoholic Fatty Liver Disease through Changes in Gut Microbiome and Intestinal Epithelial Barrier. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.97568] [Reference Citation Analysis]
23 Ukiya M, Motegi K, Sato D, Kimura H, Satsu H, Koketsu M, Ninomiya M, Myint LM, Nishina A. Effect of Compounds from Moringa oleifera Lam. on in Vitro Non-Alcoholic Fatty Liver Disease (NAFLD) Model System. Chem Biodivers 2021;18:e2100243. [PMID: 34128328 DOI: 10.1002/cbdv.202100243] [Reference Citation Analysis]
24 Ma N, Wang YK, Xu S, Ni QZ, Zheng QW, Zhu B, Cao HJ, Jiang H, Zhang FK, Yuan YM, Zhang EB, Chen TW, Xia J, Ding XF, Chen ZH, Zhang XP, Wang K, Cheng SQ, Qiu L, Li ZG, Yu YC, Wang XF, Zhou B, Li JJ, Xie D. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nat Commun 2021;12:3059. [PMID: 34031390 DOI: 10.1038/s41467-021-23285-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
25 Liao S, He H, Zeng Y, Yang L, Liu Z, An Z, Zhang M. A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1. Open Med (Wars) 2021;16:773-85. [PMID: 34041361 DOI: 10.1515/med-2021-0286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
27 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 26.0] [Reference Citation Analysis]
28 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ko M, Kamimura K, Owaki T, Nagoya T, Sakai N, Nagayama I, Niwa Y, Shibata O, Oda C, Morita S, Kimura A, Inoue R, Setsu T, Sakamaki A, Yokoo T, Terai S. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. Dis Model Mech 2021;14:dmm048922. [PMID: 33787507 DOI: 10.1242/dmm.048922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
30 Diesinger T, Lautwein A, Buko V, Belonovskaya E, Lukivskaya O, Naruta E, Kirko S, Andreev V, Dvorsky R, Buckert D, Bergler S, Renz C, Müller-Enoch D, Wirth T, Haehner T. ω-Imidazolyl-alkyl derivatives as new preclinical drug candidates for treating non-alcoholic steatohepatitis. Physiol Rep 2021;9:e14795. [PMID: 33769703 DOI: 10.14814/phy2.14795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Milaciu MV, Ciumărnean L, Matei DM, Vesa ȘC, Sabin O, Bocșan IC, Pop RM, Negrean V, Buzoianu AD, Acalovschi M. Cytokines, paraoxonase-1, periostin and non-invasive liver fibrosis scores in patients with non-alcoholic fatty liver disease and persistently elevated aminotransferases: A pilot study. Exp Ther Med 2021;21:533. [PMID: 33815606 DOI: 10.3892/etm.2021.9965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shi M, Liu P, Li J, Su Y, Zhou X, Wu C, Chen X, Zheng C. The performance of noninvasive indexes of adults in identification of nonalcoholic fatty liver disease in children. J Diabetes 2021;13:744-53. [PMID: 33576570 DOI: 10.1111/1753-0407.13169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Huang P, Tu B, Liao HJ, Huang FZ, Li ZZ, Zhu KY, Dai F, Liu HZ, Zhang TY, Sun CZ. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Sci Rep 2021;11:5886. [PMID: 33723340 DOI: 10.1038/s41598-021-85421-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
34 Fennoun H, Mansouri SE, Tahiri M, Haraj NE, Aziz SE, Hadad F, Hliwa W, Badr W, Chadli A. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. Pan Afr Med J 2020;37:270. [PMID: 33598084 DOI: 10.11604/pamj.2020.37.270.9087] [Reference Citation Analysis]
35 Ying Y, Zhang H, Yu D, Zhang W, Zhou D, Liu S. Gegen Qinlian Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats via Oxidative Stress, Inflammation, and the NLRP3 Signal Axis. Evid Based Complement Alternat Med 2021;2021:6659445. [PMID: 33643422 DOI: 10.1155/2021/6659445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Becker AK, Dörr M, Felix SB, Frost F, Grabe HJ, Lerch MM, Nauck M, Völker U, Völzke H, Kaderali L. From heterogeneous healthcare data to disease-specific biomarker networks: A hierarchical Bayesian network approach. PLoS Comput Biol 2021;17:e1008735. [PMID: 33577591 DOI: 10.1371/journal.pcbi.1008735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
37 Guo W, Kim SH, Wu D, Li L, Ortega EF, Thomas M, Meydani SN, Meydani M. Dietary Fruit and Vegetable Supplementation Suppresses Diet-Induced Atherosclerosis in LDL Receptor Knockout Mice. The Journal of Nutrition 2021;151:902-10. [DOI: 10.1093/jn/nxaa410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Wu SJ, Huang WC, Yu MC, Chen YL, Shen SC, Yeh KW, Liou CJ. Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2021;91:108602. [PMID: 33548473 DOI: 10.1016/j.jnutbio.2021.108602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
39 Dai C, Tang Z, Li X, Chen T. High-pressure homogenization and tailoring of size-tunable Ganoderma lucidum spore oil nanosystem for enhanced anticancer therapy. Chemical Engineering Journal 2021;406:127125. [DOI: 10.1016/j.cej.2020.127125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Cai H, Bai Z, Ge RL. Hypoxia-inducible factor-2 promotes liver fibrosis in non-alcoholic steatohepatitis liver disease via the NF-κB signalling pathway. Biochem Biophys Res Commun 2021;540:67-74. [PMID: 33450482 DOI: 10.1016/j.bbrc.2021.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Duriez M, Jacquet A, Hoet L, Roche S, Bock MD, Rocher C, Haussy G, Vigé X, Bocskei Z, Slavnic T, Martin V, Guillemot JC, Didier M, Kannt A, Orsini C, Mikol V, Fèvre AL. A 3D Human Liver Model of Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2020;8:359-70. [PMID: 33447518 DOI: 10.14218/JCTH.2020.00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
42 Treska V, Skalicky T, Liska V, Fichtl J, Bruha J. Liver resections for colorectal liver metastases in elderly patients. Eur Surg 2021;53:66-74. [DOI: 10.1007/s10353-020-00685-6] [Reference Citation Analysis]
43 Bartsch LM, Damasio MPS, Subudhi S, Drescher HK. Tissue-Resident Memory T Cells in the Liver-Unique Characteristics of Local Specialists. Cells 2020;9:E2457. [PMID: 33187162 DOI: 10.3390/cells9112457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
44 Elsayed HRH, El-Nablaway M, Othman BH, Abdalla AM, El Nashar EM, Abd-Elmonem MM, El-Gamal R. Can Dasatinib Ameliorate the Hepatic changes, Induced by Long Term Western Diet, in Mice? Ann Anat 2021;234:151626. [PMID: 33144268 DOI: 10.1016/j.aanat.2020.151626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Lee J, Kim HS, Cho YK, Kim EH, Lee MJ, Bae IY, Jung CH, Park JY, Kim HK, Lee WJ. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. Sci Rep 2020;10:18323. [PMID: 33110139 DOI: 10.1038/s41598-020-75266-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Sven M F, Pierre B, Manal F A, Quentin M A, Elisabetta B, Vlad R, Philippe HM, Bruno S, Jean-Louis J, Pierre B, Jean-Louis A. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. Contemp Clin Trials 2020;98:106170. [PMID: 33038502 DOI: 10.1016/j.cct.2020.106170] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
47 Mosca A, Panera N, Crudele A, Alisi A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert Review of Gastroenterology & Hepatology 2020;14:1035-46. [DOI: 10.1080/17474124.2020.1801413] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
48 Khafagy GM, Darwish HA, Yosry A, Zayed NA, Khairy AM, Elmeshmeshy EI, Elnahas HG. Non Alcoholic Fatty Liver Disease and Degree of Steatosis in Diabetic and Non- Diabetic patients. Obesity Medicine 2020;19:100243. [DOI: 10.1016/j.obmed.2020.100243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Khalifa O, Errafii K, Al-Akl NS, Arredouani A. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Dis Markers 2020;2020:8822859. [PMID: 33133304 DOI: 10.1155/2020/8822859] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
50 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
51 Pannala VR, Estes SK, Rahim M, Trenary I, O’brien TP, Shiota C, Printz RL, Reifman J, Oyama T, Shiota M, Young JD, Wallqvist A. Mechanism-based identification of plasma metabolites associated with liver toxicity. Toxicology 2020;441:152493. [DOI: 10.1016/j.tox.2020.152493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
52 Lin H, Zhu L, Baker SS, Baker RD, Lee T. Secreted phosphoglucose isomerase is a novel biomarker of nonalcoholic fatty liver in mice and humans. Biochem Biophys Res Commun 2020;529:1101-5. [PMID: 32819571 DOI: 10.1016/j.bbrc.2020.06.126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Pan X, Xie X, Peng H, Cai X, Li H, Hong Q, Wu Y, Lin X, Xu S, Peng XE. Risk Prediction for Non-alcoholic Fatty Liver Disease Based on Biochemical and Dietary Variables in a Chinese Han Population. Front Public Health 2020;8:220. [PMID: 32714888 DOI: 10.3389/fpubh.2020.00220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother 2021;55:65-79. [PMID: 32571083 DOI: 10.1177/1060028020935105] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
55 Cheng CC, Yang WY, Hsiao MC, Lin KH, Lee HW, Yuh CH. Transcriptomically Revealed Oligo-Fucoidan Enhances the Immune System and Protects Hepatocytes via the ASGPR/STAT3/HNF4A Axis. Biomolecules 2020;10:E898. [PMID: 32545625 DOI: 10.3390/biom10060898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Katsiki N, Ferrannini E, Mantzoros C. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020;107:154218. [DOI: 10.1016/j.metabol.2020.154218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pinoé-Schmidt M, van Helden J, Schiller J, Weiskirchen R. Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation. Cells 2020;9:E1346. [PMID: 32481590 DOI: 10.3390/cells9061346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
58 Zanieri F, Levi A, Montefusco D, Longato L, De Chiara F, Frenguelli L, Omenetti S, Andreola F, Luong TV, Massey V, Caballeria J, Fondevila C, Shanmugavelandy SS, Fox T, Mazza G, Argemi J, Bataller R, Cowart LA, Kester M, Pinzani M, Rombouts K. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. Cells 2020;9:E1237. [PMID: 32429478 DOI: 10.3390/cells9051237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
59 Weiskirchen R. Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis". Cells 2020;9:E1105. [PMID: 32365575 DOI: 10.3390/cells9051105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Amoorahim M, Ashrafi-Kooshk MR, Esmaeili S, Shahlaei M, Moradi S, Khodarahmi R. Physiological changes in the albumin-bound non-esterified free fatty acids critically influence heme/bilirubin binding properties of the protein: A comparative, in vitro, spectroscopic study using the endogenous biomolecules. Spectrochim Acta A Mol Biomol Spectrosc 2020;235:118298. [PMID: 32294588 DOI: 10.1016/j.saa.2020.118298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Liu R, Wu K, Li Y, Sun R, Li X. Human antigen R: A potential therapeutic target for liver diseases. Pharmacol Res 2020;155:104684. [PMID: 32045667 DOI: 10.1016/j.phrs.2020.104684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
62 Romão MH, de Bem GF, Santos IB, de Andrade Soares R, Ognibene DT, de Moura RS, da Costa CA, Resende ÂC. Açaí (Euterpe oleracea Mart.) seed extract protects against hepatic steatosis and fibrosis in high-fat diet-fed mice: Role of local renin-angiotensin system, oxidative stress and inflammation. Journal of Functional Foods 2020;65:103726. [DOI: 10.1016/j.jff.2019.103726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
63 Kaya E, Yilmaz Y. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 van der Heide D, Weiskirchen R, Bansal R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front Immunol 2019;10:2852. [PMID: 31849997 DOI: 10.3389/fimmu.2019.02852] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 29.3] [Reference Citation Analysis]
65 Yi R, Tan F, Liao W, Wang Q, Mu J, Zhou X, Yang Z, Zhao X. Isolation and Identification of Lactobacillus plantarum HFY05 from Natural Fermented Yak Yogurt and Its Effect on Alcoholic Liver Injury in Mice. Microorganisms 2019;7:E530. [PMID: 31694208 DOI: 10.3390/microorganisms7110530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
66 Zhou Y, Tan F, Li C, Li W, Liao W, Li Q, Qin G, Liu W, Zhao X. White Peony (Fermented Camellia sinensis) Polyphenols Help Prevent Alcoholic Liver Injury via Antioxidation. Antioxidants (Basel) 2019;8:E524. [PMID: 31683564 DOI: 10.3390/antiox8110524] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]